1-(3-溴-4-甲氧基苯基)-1,3-丙二醇 | 1007390-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(3-溴-4-甲氧基苯基)-1,3-丙二醇
• 英文名称: 1-(3-bromo-4-methoxyphenyl)-1,3-propanediol
• 英文别名: (S)-1-(3-Bromo-4-methoxyphenyl)-1,3-propanediol；1-(3-bromo-4-methoxyphenyl)propane-1,3-diol
• CAS: 1007390-23-9
• 化学式: C₁₀H₁₃BrO₃
• 分子量: 261.115
• InChiKey: SUFNYFONQOZHFS-UHFFFAOYSA-N

物化性质

• 沸点：
  402.5±45.0 °C(Predicted)
• 密度：
  1.494±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3-溴-4-甲氧基苯基)-1,3-丙二醇 、 阿德福韦 在 吡啶 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 、
  参考文献：
  名称：

  Pradefovir: A Prodrug That Targets Adefovir to the Liver for the Treatment of Hepatitis B

  摘要：

  Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity. In an effort to improve the therapeutic index of adefovir, 1-aryl-1,3-propanyl prodrugs were synthesized with the rationale that this selectively liver-activated prodrug class would enhance liver levels of the active metabolite adefovir diphosphate (ADV-DP) and/or decrease kidney exposure. The lead prodrug (14, MB06866, pradefovir), identified from a variety of in vitro and in vivo assays, exhibited good oral bioavailability (F = 42%, mesylate salt, rat) and rate of prodrug conversion to ADV-DP. Tissue distribution studies in the rat using radiolabeled materials showed that cyclic 1-aryl-1,3-propanyl prodrugs enhance the delivery of adefovir and its metabolites to the liver, with pradefovir exhibiting a 12-fold improvement in the liver/kidney ratio over adefovir dipivoxil.

  DOI：

  10.1021/jm7012216
• 作为产物：
  描述：

  Ethyl 3-(3-bromo-4-methoxyphenyl)-3-hydroxypropanoate 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 1-(3-溴-4-甲氧基苯基)-1,3-丙二醇
  参考文献：
  名称：

  Pradefovir: A Prodrug That Targets Adefovir to the Liver for the Treatment of Hepatitis B

  摘要：

  Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity. In an effort to improve the therapeutic index of adefovir, 1-aryl-1,3-propanyl prodrugs were synthesized with the rationale that this selectively liver-activated prodrug class would enhance liver levels of the active metabolite adefovir diphosphate (ADV-DP) and/or decrease kidney exposure. The lead prodrug (14, MB06866, pradefovir), identified from a variety of in vitro and in vivo assays, exhibited good oral bioavailability (F = 42%, mesylate salt, rat) and rate of prodrug conversion to ADV-DP. Tissue distribution studies in the rat using radiolabeled materials showed that cyclic 1-aryl-1,3-propanyl prodrugs enhance the delivery of adefovir and its metabolites to the liver, with pradefovir exhibiting a 12-fold improvement in the liver/kidney ratio over adefovir dipivoxil.

  DOI：

  10.1021/jm7012216

文献信息

• Electrochemical ring-opening 1,3-dihydroxylation of arylcyclopropanes with H₂O
  作者：Jianhua Cai、Yuxi Wen、Wei Sheng、Xuejin Huang、Ye Zheng、Chunlan Song、Jiakun Li

  DOI：10.1039/d3gc02283h

  日期：——

  dihydroxylation of alkenes is one of the most powerful synthetic tools for delivering two hydroxyl groups at vicinal positions. The direct formation of 1,3-diols remains a formidable challenge, yet dihydroxyl groups are broadly present in bioactive compounds, and are currently only available synthetically via multiple steps. The oxidative ring-opening of arylcyclopropanes has been demonstrated to access various

  传统的烯烃二羟基化是在邻位提供两个羟基的最强大的合成工具之一。直接形成 1,3-二醇仍然是一个艰巨的挑战，但二羟基广泛存在于生物活性化合物中，目前只能通过多个步骤合成。芳基环丙烷的氧化开环已被证明可以得到各种 1,3-双官能化化学物质，但由于 1,3-二醇本身很容易被进一步氧化，所以尚未直接合成 1,3-二醇。在此，我们报告了一种简便有效的 1,3-二醇策略，涉及用 H 2控制芳基环丙烷的电化学 C-C 键断裂O作为最终的绿色羟基源。此外，该方案以其高原子经济性、广泛的底物范围和优异的官能团耐受性而脱颖而出，因此适合复杂天然产物和药物衍生物的合成。
• Pradefovir: A Prodrug That Targets Adefovir to the Liver for the Treatment of Hepatitis B
  作者：K. Raja Reddy、Michael C. Matelich、Bheemarao G. Ugarkar、Jorge E. Gómez-Galeno、Jay DaRe、Kristin Ollis、Zhili Sun、William Craigo、Timothy J. Colby、James M. Fujitaki、Serge H. Boyer、Paul D. van Poelje、Mark D. Erion

  DOI：10.1021/jm7012216

  日期：2008.2.1

  Adefovir dipivoxil, a marketed drug for the treatment of hepatitis B, is dosed at submaximally efficacious doses because of renal toxicity. In an effort to improve the therapeutic index of adefovir, 1-aryl-1,3-propanyl prodrugs were synthesized with the rationale that this selectively liver-activated prodrug class would enhance liver levels of the active metabolite adefovir diphosphate (ADV-DP) and/or decrease kidney exposure. The lead prodrug (14, MB06866, pradefovir), identified from a variety of in vitro and in vivo assays, exhibited good oral bioavailability (F = 42%, mesylate salt, rat) and rate of prodrug conversion to ADV-DP. Tissue distribution studies in the rat using radiolabeled materials showed that cyclic 1-aryl-1,3-propanyl prodrugs enhance the delivery of adefovir and its metabolites to the liver, with pradefovir exhibiting a 12-fold improvement in the liver/kidney ratio over adefovir dipivoxil.